Deep learning transforms the drug discovery process in collaboration between Insilico Medicine and Life Extension

In March 2016 Insilico Medicine initiated a research collaboration with Life Extension to apply advanced bioinformatic methods and deep learning algorithms to screen for naturally occurring compounds that may slow down or even reverse the cellular and molecular mechanisms of aging. Today Life Extension (LE) launched a new line of nutraceuticals called GEROPROTECTTM, and the first product in the series called Ageless CellTM combines some of the natural compounds that were shortlisted by Insilico Medicine's algorithms and are generally recognized as safe (GRAS). "Life Extension's mission is to extend the healthy human lifespan; and as such, we are focused on identifying natural products with critical health and wellness properties," said Andrew G. Swick, PhD, senior vice president of scientific affairs, discovery research and product development for Life Extension. "Our collaboration with Insilico Medicine fostered a novel approach to formulating anti-aging supplements utilizing artificial intelligence and sophisticated biologically-inspired algorithms and resulted in the very first AI formulated supplement," Swick said. The global nutraceuticals market was valued at US$165.62 billion in 2014 by Transparency Market Research and is expected to reach US$278.96 billion by 2021.